Ana De Jesus-Acosta

Assistant Professor


Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Ana De Jesus-Acosta is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Open Access
  • Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/ mismatch repair–deficient cancer: Results from the phase II KEYNOTE-158 study

    Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., de Jesus-Acosta, A., Delord, J. P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., Piha-Paul, S. A., Doi, T., Gao, B., Chung, H. C., Lopez-Martin, J., Bang, Y. J., Frommer, R. S., Shah, M., Ghori, R., Joe, A. K. & 2 others, Pruitt, S. K. & Diaz, L. A., 2020, In : Journal of Clinical Oncology. 38, 1, p. 1-10 10 p.

    Research output: Contribution to journalArticle

  • Effect of Gemcitabine and nab-Paclitaxel with or Without Hydroxychloroquine on Patients with Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial

    Karasic, T. B., O'Hara, M. H., Loaiza-Bonilla, A., Reiss, K. A., Teitelbaum, U. R., Borazanci, E., De Jesus-Acosta, A., Redlinger, C., Burrell, J. A., Laheru, D. A., Von Hoff, D. D., Amaravadi, R. K., Drebin, J. A. & O'Dwyer, P. J., Jul 2019, In : JAMA Oncology. 5, 7, p. 993-998 6 p.

    Research output: Contribution to journalArticle

  • Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

    De Jesus-Acosta, A., Sugar, E. A., O’Dwyer, P. J., Ramanathan, R. K., Von Hoff, D. D., Rasheed, Z., Zheng, L., Begum, A., Anders, R., Maitra, A., McAllister, F., Nv, R. K., Yabuuchi, S., de Wilde, R. F., Batukbhai, B., Sahin, I. & Laheru, D. A., Jan 1 2019, (Accepted/In press) In : British Journal of Cancer.

    Research output: Contribution to journalArticle